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1. Introduction 
It is estimated that the human genome incurs on the order of 1, 000-1,000,000 DNA 
lesions/cell/day (Lodish 2000). A majority of these are thought to be due to endogenous 
sources, including reactive oxygen and nitrogen species (ROS, RNS) that can oxidize cellular 
macromolecules including lipid, protein and nucleic acid. These free radicals can  be 
generated for specific purposes by cellular enzymes; for example, nitric oxide synthases 
generate NO in endothelial cells for signaling purposes, while NADPH oxidase and 
myeloperoxidase generate ROS in granulocytes to kill invading pathogens. However, ROS 
can also occur as a byproduct of cellular energy metabolism (Beckman and Ames 1998). 
Most cells use mitochondrial respiration as a means of energy production. The process of 
moving electrons across the mitochondrial membrane can at some frequency result in their 
transfer to molecular oxygen and the generation of superoxide and hydrogen peroxide, 
which together can generate the highly reactive hydroxyl radical and damage nearby 
molecules, including DNA.  
The frequency of superoxide formation is influenced by many factors, including the rate of 
electron transport and the capacity of the mitochondria to couple the proton gradient created 
across the inner membrane to ATP production, or to dissipate it in the form of heat through 
the use of uncoupling proteins. High rates of electron transport and efficient ATP production 
or uncoupling are consistent with reduced ROS generation, while low rates of transport or 
inefficient ATP production (for example when ATP/ADP ratios are already high) are 
consistent with increased ROS generation. Different substrates may also influence 
mitochondrial ROS production. Oxidation of ketone bodies, for example, may generate more 
ROS than oxidation of acetyl CoA from glucose (Tieu et al. 2003). Substrate utilization further 
depends on cell type and nutritional status. For example, neurons prefer to oxidize glucose, 
but can also use ketone bodies derived from fat oxidation in the liver. Skeletal muscle can use 
either fat or glucose, depending on availability, but tends to use one at the exclusion of the 
other (Randle et al. 1963). In cooperation with mitochondria, peroxisomes also play a major 
role in energy metabolism by oxidizing long-chain fatty acids. Peroxisomes can further 
participate in ketogenesis, amino acid oxidation and the oxidative phase of the pentose 
phosphate pathway depending on substrate availability. Like mitochondria, they are a major 
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source of ROS and RNS generating enzymes, and thus a potential source of oxidative 
macromolecular damage by leakage of ROS/RNS across the organelle membrane. 
Mitochondria and peroxisomes also produce abundant amounts of antioxidants enzymes such 
as superoxide dismutase and catalase to neutralize ROS. Thus, mitochondria and peroxisomes 
can both contribute to ROS as well as play a role in ROS detoxification. 
In order to generate energy efficiently, cells oxidize carbon units derived from glucose, 
amino acids or fatty acids in mitochondria. The use of these substrates is governed by 
nutritional status and is further subject to hormonal control. Insulin and glucagon are major 
regulators of organismal substrate utilization. In the fed state, elevated blood glucose 
promotes insulin secretion by the pancreas and transport of glucose into insulin-responsive 
tissues including liver, muscle and fat. In the liver, glucose is stored as glycogen or used as a 
substrate for de novo lipogenesis. Insulin signaling also inhibits release of free fatty acids 
from white adipose tissue and promotes de novo lipogenesis and dietary lipid repackaging in 
the liver for storage in white adipose tissue. After a meal, glucose levels fall and counter-
regulatory hormones such as glucagon reverse the actions of insulin and glucose by 
promoting hepatic glycogenolysis and gluconeogenesis for glucose-dependent tissues such 
as red blood cells and neurons, and release of fatty acids from the white adipose tissue for 
oxidation in other organs. Defects in insulin signaling caused by overeating are associated 
with a spectrum of pathologies including diabetes, obesity and atherosclerosis collectively 
known as the metabolic syndrome. Although the underlying mechanisms are not entirely 
clear, it is associated with chronic inflammation and oxidative stress (Hotamisligil 2006). In 
stark contrast to metabolic syndrome is the spectrum of phenotypes associated with dietary 
restriction (DR, also known as calorie restriction), defined as reduced food intake without 
malnutrition. Originally described in rodents to reduce the incidence of cancer and extend 
lifespan (McCay, Crowel, and Maynard 1935), DR has proven efficacy at increasing lifespan, 
stress resistance and metabolic fitness in a wide range of experimental organisms. In 
mammals, the DR state is characterized by reduced serum glucose, reduced growth factors 
and growth factor signaling, improved insulin sensitivity, increased resistance to oxidative 
stress and reduced adiposity (Fontana and Klein 2007). While the molecular mechanisms 
underlying the benefits of DR remain unclear, reduced steady state levels of 
macromolecular oxidative damage suggest reduced ROS production and/or increased 
antioxidant defenses play a role.  
When DNA damage occurs, there are a number of overlapping repair pathways that 
recognize and remove the damage, as well as a battery of signaling pathways that influence 
immediate decisions on cell fate and longer-term adaptations to stress. DNA damage repair 
pathways are distinguished in large part by the lesions that they recognize. Oxidative base 
lesions are typically recognized by the base excision repair (BER) pathway, while bulky 
helix distorting lesions are typically removed by the nucleotide excision repair (NER) 
pathway. Although the latter is chiefly responsible for removal of UV lesions from sunlight, 
endogenous oxidative lesions are also partially dependent on NER pathways (Brooks et al. 
2000). Oxidative stress can also cause breaks in the sugar-phosphate backbone, resulting in 
single strand breaks that can interrupt transcription or replication. When the density of such 
breaks is high, they can occur nearby on opposite strands and result in double strand 
breaks. Such lesions can be repaired by homologous recombination in the presence of a 
sister chromatid (for example during S phase of the cell cycle) or by non-homologous 
recombination during other phases of the cell cycle when the sister chromatid is not readily 
available to serve as a template for repair.  The so-called DNA damage response (DDR) is 
www.intechopen.com
Relationship between DNA Damage and Energy Metabolism:  
Evidence from DNA Repair Deficiency Syndromes 
 
663 
not a single response but a network of signaling and repair pathways activated by genotoxic 
stress. Upon DNA damage such as a double strand break or a collapsed replication fork, the 
serine/threonine kinases ATM or ATR, respectively, initiate a cascade of cellular responses 
resulting in cell cycle arrest and recruitment of repair factors. One of the targets of ATM and 
ATR is the tumor suppressor p53, which is stabilized by phosphorylation and activates 
transcription of genes involved in cell fate, including apoptosis or senescence. Other 
proteins such as poly ADP ribose polymerase (PARP) are activated by DNA damage and 
can have indirect effects on cell fate decisions by depleting ATP and NAD+. 
Given the connection between production of ROS by cellular metabolism and DNA damage, 
one might predict coordinate regulation of the cellular response to DNA damage and 
growth and metabolism on the cellular and organismal levels. In this chapter, we will 
discuss existing evidence of such a connection. First, we will consider metabolic changes 
associated with defects in NER disorders and their resemblance to the adaptive response to 
DR, particularly in mouse models of these diseases. Next, we will consider metabolic 
changes in a variety of other DNA damage repair and signaling disorders, ranging from DR-
like phenotypes to metabolic disorder. We will conclude by reviewing the evidence linking 
DNA damage repair and signaling pathways directly and indirectly to changes in cellular 
growth and energy metabolism. 
2. Metabolic defects in nucleotide excision repair deficiency syndromes 
Although the mutations causing the segmental progerias Cockayne syndrome (CS) and 
trichothiodystrophy (TTD) are known, how alterations in the associated nucleotide excision 
DNA repair proteins cause pleiotrophic disease symptoms including dwarfism and cachexia 
are not yet clear. In mouse models of these disorders, unrepaired endogenous DNA damage 
is linked to perturbations in energy metabolism and alterations in insulin/insulin-like 
growth factor-1 (IGF-1) signaling. Paradoxically, these changes resemble beneficial adaptive 
responses to DR associated with improved metabolic fitness and extended longevity. In this 
section, we will discuss perturbations in growth and energy metabolism associated with 
defects in NER proteins in human disease and mouse models, and the potential role of DNA 
damage in eliciting these changes. 
2.1 Cockayne syndrome and trichothiodystrophy  
NER is an evolutionarily conserved pathway required for the removal of UV-induced DNA 
damage. It is divided into two branches based on how the lesion is initially recognized. 
Global genome (GG)-NER can occur anywhere in the genome upon recognition of DNA 
helical distortions by the XPC/HR23B/CEN2 complex. Transcription-coupled (TC)-NER 
occurs only on the transcribed DNA strand and is initiated by the stalling of an elongating 
RNA polymerase, for example by steric hindrance at the site of a bulky adduct. TC-NER 
specific proteins CSA and CSB participate in the upstream events surrounding the stalling of 
an RNA polymerase at the site of DNA damage. Although both CSA and CSB are involved 
in ubiquitination and protein turnover – CSA is a component of a ubiquitin ligase complex 
(Groisman et al. 2003), and CSB contains a ubiquitin-binding domain required for UV 
damage repair  (Anindya et al. 2010) - their exact roles in TC-NER remain unclear. Once the 
TC-NER or GG-NER machinery recognizes the lesion, the helicases XPB and XPD unwind 
the damaged DNA, allowing validation of the lesion by XPA, endonuclealytic cleavage of 
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the phosphodiester backbone by XPG and XPF-ERCC1 and removal of the damaged 
oligonucleotide in preparation for repair DNA synthesis.  
Mutations in CSA, CSB, XPG, XPD and XPB are associated with CS, a rare progressive 
disease characterized by photosensitivity, dwarfism, loss of subcutaneous fat and 
neurodegeneration.  CS was first described by Edward Cockayne in 1936 (Cockayne 1936). 
To date, approximately 200 cases have been reported in the literature (Nance and Berry 
1992; Ozdirim et al. 1996; Pasquier et al. 2006; Rapin et al. 2006). Despite UV sensitivity, CS 
is not associated with an elevated risk of skin cancer as observed in the related NER 
deficiency syndrome xeroderma pigmentosum (XP). Although there is a range in the onset 
and severity of CS, typical presentation involves normal in utero growth and birth weight 
followed by a profound postnatal growth failure within the first two years. This growth 
failure is also observed in the postnatal brain, resulting in developmental microcephaly and 
cognitive impairment. Neuropathological defects include demyelination and atrophy of 
white matter, calcification of the basal ganglia, cerebellar atrophy, demyelination of 
peripheral nerves, retinopathy, and neuronal loss in the inner ear (Weidenheim, Dickson, 
and Rapin 2009). Based on the involvement of white matter, CS is considered a form of 
leukodystrophy. Interestingly, such white matter diseases can be caused by various genetic 
defects in lysosome or peroxisome metabolism and typically present postnatally after 
normal birth and early development (Kohlschutter et al. 2010).  Diabetes mellitus, early 
hypertension and atherosclerosis are also prevalent in CS (Rapin et al. 2006). Besides the 
nervous system and adipose tissue, other organ systems appear proportionately smaller in 
size yet unimpaired (Weidenheim, Dickson, and Rapin 2009). Death occurs around 12 years 
of age often from cachexia or an intercurrent illness such as respiratory infection. 
The fact that weight is more affected than height in CS led to the use of the term cachexia, or 
wasting, in association with this disease (Nance and Berry 1992). Although it is not clear that 
lean mass is preferentially affected as is typical with cachexia, adipose tissue is clearly 
affected. CS is classified as a lipodystrophy, indicating the abnormal redistribution of fat.  
Subcutaneous fat loss leads to sunken eyes and a wizened appearance that are further 
defining characteristics of the disease. Adipocytes are a major site of energy storage in the 
form of triglycerides, as well as a source of lipokines involved in a variety of processes 
including appetite control, immune function and temperature regulation. CS patients 
presumably still have functioning adipocytes that can produce adipokines but do not store 
triglycerides for reasons that remain unclear. This is distinct from generalized lipoatrophy, 
in which adipocytes and associated adiopkines are lost, resulting in hyperlipidemia and 
insulin resistance despite the paucity of fat. Interestingly, lipids are also a major component 
of myelin sheaths that are lost in CS, although no connection between altered lipid 
metabolism and demyelination has been reported. 
The cause of dwarfism in CS is not known; however there are no consistent data to suggest 
alteration of endocrine function (Rapin et al. 2006; Nance and Berry 1992). For example, 
growth hormone (GH) levels are normal to elevated. Whether or not transient perturbation 
of GH/IGF-1 signaling, which has been reported in mouse models (see below), is relevant in 
the human disease remains unknown.   
Mutations in XPD and XPB, as well as another TFIIH component, p8, can cause another 
photosensitivity disorder with characteristic growth failure and neurological involvement 
known as TTD (Morice-Picard et al. 2009). Unlike CS, TTD patients present with 
characteristic brittle hair and nails caused by a transcriptional defect in terminally 
differentiating keratinocytes.  Despite this difference, there are many similarities between 
www.intechopen.com
Relationship between DNA Damage and Energy Metabolism:  
Evidence from DNA Repair Deficiency Syndromes 
 
665 
the diseases as would be expected if they share a common basis in defective transcription-
coupled DNA repair. As with CS, TTD shows no increase skin cancer risk despite 
photosensitivity. TTD patients also demonstrate dysmyelination and lipodystrophy. Despite 
the hypothesis that CS and TTD share a common basis in defect transcription-coupled  
DNA repair (Andressoo, Hoeijmakers, and Mitchell 2006), this is by no means the only 
hypothesis regarding the etiology of these diseases. For example, the requirement for the 
CAK complex of TFIIH in the phosphorylation and regulation of nuclear hormone receptors, 
which play a major role in cellular and organismal metabolism, has led to the competing 
hypothesis that disease symptoms are caused by defects in gene expression regulated  
by these transcriptional activators (Compe et al. 2007; Keriel et al. 2002; Brooks, Cheng,  
and Cooper 2008). 
2.2 Mouse models of NER progeria  
Mouse models of CS engineered by disabling the CSA or CSB genes share some 
characteristics of human CS but in a milder form. Knockout mice are born normally, but are 
photosensitive and display an age-dependent loss of photoreceptor cells (van der Horst et 
al. 2002; van der Horst et al. 1997). Although they develop normally, CSB mice remain lean 
in adulthood and have normal lifespans (Dolle et al. 2006). Interestingly, CSA and CSB mice 
are resistant to renal ischemia reperfusion injury, a form of acute oxidative and 
inflammatory stress, and display improved glucose tolerance and insulin sensitivity (Susa et 
al. 2009). Both of these phenotypes are typical of DR mice (Mitchell et al. 2009). TTD mice 
created by mutating residue 722 from an R to a W in the XPD C terminus faithfully 
recapitulate the brittle hair phenotype of the human TTD, but like the CS mice have an 
overall milder phenotype than the corresponding human disease (de Boer et al. 1998). TTD 
mice display end of life pathologies consistent with both accelerated aging (osteoporosis, 
aortic sarcopenia, lymphoid depletion) as well as DR (reduced inflammatory dermatitis, 
reduced pituitary adenoma, reduced subcutaneous fat) (Wijnhoven et al. 2005). Duodenal 
epithelial hyperplasia has been proposed to play a role in reduced food absorbance leading 
to the overall DR-like phenotype (Wijnhoven et al. 2005). XP-CS mice, engineered with a 
different point mutation in the XPD gene (G602D) associated in patients with the symptoms 
of both CS and XP also recapitulate the mild features of mouse CS as well as the severe skin 
cancer susceptibility of XP (Andressoo et al. 2006). 
Another group of mouse models of NER deficiency share a more severe core phenotype of 
dwarfism, ataxia, failure to thrive and death before weaning at 3-4 weeks of age. This so-
called “NER progeria” was first described in mice lacking the endonuclease Ercc1 (Melton et 
al. 1998; Weeda et al. 1997) and subsequently in a number of genetic models of NER 
deficiency, including CSB/XPA (Murai et al. 2001), XPA/TTD (de Boer et al. 1998), 
XPA/XPCS (Andressoo et al. 2006), CSB/XPC (Laposa, Huang, and Cleaver 2007) double 
homozygous mutants as well as XPG (Sun et al. 2003) and XPF (Tian et al. 2004) single 
homozygous mutants.  
Common metabolic features of NER progeria in mice include reduced blood glucose and 
reduced insulin, disproportionate reduction of white adipose tissue weight, and 
accumulation of triglycerides in the liver (van de Ven et al. 2007). Although the cause of 
death is not clear, animals may inevitably succumb to hypoglycemia. Reduced food intake 
does not seem to be the cause of metabolic perturbations. Liver transcriptome analysis of 
Ercc1-/- and CSB/XPA mice revealed altered expression of genes involved in carbohydrate 
and oxidative metabolism and peroxisome biogenesis suggestive of increased glycogen 
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synthesis, decreased glycolysis, and decreased oxidative metabolism (Niedernhofer et al. 
2006). Global metabolic profiling by NMR revealed that Ercc1-/- mice have altered lipid and 
energy metabolism and a shift toward ketosis when compared to age-matched controls 
(Nevedomskaya et al. 2010). Ercc1-/- mice show several metabolic adaptations that resemble 
those seen in DR, including decreased LDL and VLDL, increased HDL, and decreased 
serum glucose (Nevedomskaya et al. 2010).  
Another common feature of NER progeria that may underlie the growth retardation is 
reduced mRNA and serum protein expression of IGF-1 (Niedernhofer et al. 2006; van der 
Pluijm et al. 2007; van de Ven et al. 2006). Unlike long-lived endocrine deficient dwarfs 
(Ames, Snell) with reduced GH secretion due to defective anterior pituitary development 
(Bartke and Brown-Borg 2004), NER-deficient mice have an intact pituitary and normal to 
elevated GH levels, consistent with normal hypothalamic and pituitary function. Instead, 
GH receptor mRNA levels are reduced in multiple tissues, resulting in reduced GH-
dependent IGF-1 production. Liver transcriptome analysis confirmed a general 
downregulation of multiple components of the postnatal GH/IGF-1 axis. Nonetheless, in 
select mouse models of severe NER progeria, effects on serum IGF-1 and glycemic index can 
be transient, occurring prior to weaning but normalizing in animals that survive this 
apparent developmental bottleneck (van de Ven et al. 2006). 
Global profiling of gene expression in liver confirmed a significant overlap between NER 
progeria and long-lived dwarfism (Schumacher et al. 2008) consistent with the physiologic 
data. Paradoxically, the core feature of IGF-1 signaling attenuation increases lifespan in several 
species (Rincon et al. 2004; Longo and Finch 2003) but is associated with decreased longevity in 
NER progeria. Altered growth and energy metabolism has thus been interpreted as an 
adaptive response to endogenous genotoxic stress. Whether or not this response is 
maladaptive in this model is not known, but does appear to be so in mouse models of models 
of Hutchinson-Gilford progeria syndrome (HGPS) (Marino et al. 2010) as discussed below.  
2.3 Evidence for a role of DNA repair in CD and TTD phenotypes  
What is the evidence that defects in DNA repair, and in particular TC-NER, are causative of 
the pleiotropic disease symptoms including disturbances in growth and energy metabolism? 
Most NER proteins associated with disorders in man and mouse are multifunctional with 
distinct roles in several different cellular processes. For example, CSB was originally cloned 
as a TC-NER factor, but can also function in chromatin remodeling, transcriptional initiation 
(Le May, Mota-Fernandes et al. 2010), transcriptional elongation (Le May, Egly, and Coin 
2010), BER via interactions with the BER glycosylase Ogg1 and stimulation of APE1 incision 
(Wong et al. 2007) and rRNA synthesis (Bradsher et al. 2002). Similarly, the TFIIH complex 
containing the XPB and XPD helicases plays a role in transcriptional initiation and activated 
transcription by a subset of nuclear hormone receptors (Keriel et al. 2002; Compe et al. 2007). 
Roles for many of these functions have been proposed to be causative of one or more 
symptoms of CS, TTD or XP. However, due in large part to the high degree of overlap 
between symptoms in multiple different mouse models, where the effects of homozygous 
mutations can be interrogated against a standardized genetic and environmental 
background, it has been hypothesized that these conditions have a common underlying 
cause (Andressoo, Hoeijmakers, and Mitchell 2006; van de Ven et al. 2007). Currently, the 
only known common function of each of the proteins, including CSA, CSB, XPD, XPB and 
XPG, is the transcription-coupled arm of NER. Based on current data, this makes a defect in 
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TC-NER a plausible cause of overlapping disease symptoms, but does not rule out common 
pathways that are currently unknown or untested for all relevant disease loci. 
If indeed defects in the TC-NER pathway are causative of disease symptoms, what are the 
relevant endogenous DNA lesions? Most of what is known about the function of TC-NER 
proteins is derived from cell-based experiments with UV as the source of DNA damage. UV 
irradiation produces two types of bulky lesions which are substrates for NER; cyclobutane 
pyrimidine dimers, mainly removed by TC-NER and pyrimidine 6-4 pyrimidone 
photoproducts, typically processed by GG-NER. Indeed, cells deficient in CSB fail to repair 
cyclobutane dimers but repair 6-4 photoproducts efficiently (Barrett et al. 1991).  UV light 
may possibly damage keratinocytes of CS patients, but has little capacity to induce lesions in 
other relevant tissues. Most bulky lesions are induced by exogenous sources, but some 
bulky lesions are created by endogenous sources (De Bont and van Larebeke 2004). 
8,5’-cyclopurine-2’-deoxynucleaosides (cyPudNs) are endogenous lesions formed in DNA 
by the hydroxyl radical (Jaruga, Theruvathu, et al. 2004; Dizdaroglu et al. 1987).  cyPudNs 
are chemically stable lesions which are expected to accumulate slowly and are candidates 
for lesions which could cause neurodegeneration (Kuraoka et al. 2000; Brooks 2008). 
cyPudNs block transcription and, unlike most oxidative DNA lesions, cyPudNs are repaired 
by NER rather than BER (Brooks et al. 2000; Kuraoka et al. 2000). In vitro assays using CHO 
and NER-deficient CHO cells show that ERCC1 and XPG are required for excision of the 
8,5’-(S)-cyclo-2’deoxyadenosine (cyclo-dA) lesion, while BER glycosylases are not active on 
the cyclo-dA lesion (Brooks et al. 2000). Using a host cell reactivation assay, Brooks et. al. 
found that cyclo-dA is a substrate for NER in vivo (Brooks et al. 2000). Oxidative lesions are 
elevated in and may contribute to neurodegeneration (Kruman 2004).  TC-NER may protect 
neurons from oxidative lesions, the accumulation of which may lead to the neuronal death 
observed in CS. Nonetheless, it remains controversial whether or not cells from CS patients 
or mice are hypersensitive to oxidative stress (van de Ven et al. 2006). Thus despite the 
growing literature on molecular functions of CSA, CSB and other TC-NER proteins, proof 
that unrepaired endogenous oxidative lesions cause CS and/or TTD is lacking. 
Identification of such a lesion and its target tissue awaits.  
3. Metabolic defects in other DNA repair and maintenance disorders 
A number of human syndromes and mouse models with defects in DNA damage repair and 
signaling also display perturbations in growth and energy metabolism. Some of these show 
characteristics of adaptive changes reminiscent of DR as described above in TC-NER 
syndromes, while others display insulin resistance and atherosclerosis resembling metabolic 
syndrome on the opposite end of the energy spectrum. In this section, we will  describe a 
number of syndromes and/or mouse models with known defects in DNA repair, genome 
maintenance or DNA damage-related signal transduction with an emphasis on changes in 
growth, energy metabolism, adiposity and glucose homeostasis. 
3.1 Hutchinson-Gilford Progeria Syndrome  
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare autosomal dominant progeria 
characterized by failure to thrive, growth retardation unrelated to GH deficiency, baldness 
and decreased body fat without insulin resistance (Merideth et al. 2008). Atherosclerosis is 
thought to result from the general accelerated aging observed in all tissues and organs 
rather than from elevated serum lipoproteins (Al-Shali and Hegele 2004). Vascular disease 
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and stroke are the main causes of death in HGPS, with a life expectancy of about 13 years of 
age (Merideth et al. 2008). HGPS is caused by a mutation in Lamin A, a component of the 
nuclear envelope, which leads to a truncated protein missing the Zpmste24 cleavage site 
(Merideth et al. 2008).  
Mouse models deficient in Zmpste24 exhibit nuclear architecture abnormalities, severe 
growth retardation, loss of subcutaneous adipose tissue, accumulation of lipid in ectopic 
sites such as liver, and premature death (Pendas et al. 2002; Varela et al. 2005). Aberrations 
in cardiac muscle of Zmpste24 mice include thinning of the ventricular wall, muscle 
degeneration, increased inflammation and interstitial fibrosis, suggesting that 
cardiomyopathy and heart failure contribute to death in this model (Pendas et al. 2002). 
Zmpste24 mice exhibit increased autophagy in skeletal muscle, possibly due to decreased 
circulating glucose and insulin and increased adiponectin, resulting in AMPK activation and 
suppression of the mTOR pathway (Marino et al. 2008). Gene expression data of livers of 
Zmpste24 mice indicate a shift from glucose to lipid metabolism, a response also seen in 
starvation (Marino et al. 2008). Zmpste24 mice show decreased IGF-1 and GHR expression 
in the liver, along with suppressed levels of IGF-1 and increased levels of GH in the serum 
(Marino et al. 2010). Treatment of Zmpste24 mice with recombinant IGF-1 using a 
subcutaneous minipump rescues some of the progeroid phenotypes, resulting in improved 
body weight, increased subcutaneous fat, reduced kyphosis and reduced alopecia (Marino 
et al. 2010). Serum GH levels were restored (reduced to normal) and lifespan of Zmpste24 
mice was expended by 18% by IGF-1 treatment (Marino et al. 2010).  Thus, chronic 
perturbation of the somatotroph axis in response to defects in nuclear architecture has been 
interpreted as a maladaptive response that actually accelerates disease symptoms. 
Does nuclear architecture have any impact on DNA damage repair or signaling? Evidence 
for a connection between nuclear architecture and DNA damage comes from cells of 
Zmpste24 deficient mice. These cells display increased chromosomal abnormalities and γ-
H2AX phosphorylation indicative of greater DNA damage and reduced genomic stability 
(Liu et al. 2005). Fibroblasts from HGPS patients senesce prematurely, indicating a cell-
autonomous alteration in proliferative capacity (Bridger and Kill 2004; Allsopp et al. 1992). 
Thus, alterations in nuclear architecture leading to chromosome instability can indirectly 
activate the DNA damage response (Liu et al. 2005; Verstraeten et al. 2007). 
3.2 Werner syndrome 
Werner syndrome is a segmental progeria characterized by short stature, early graying and 
loss of hair. There is no evidence for endocrine deficiency as an explanation for growth 
deficiency (Monnat 2010). Type 2 diabetes mellitus and dyslipidemia leading to 
atherosclerosis are also common features of Werner syndrome. Patients with Werner 
syndrome typically live into their mid-50s and die from premature cardiovascular disease or 
cancer (Huang et al. 2006; Martin 1985). Werner syndrome patients show accelerated brain 
accumulation of amyloid β peptide and hyperphosphorylated tau, both common in age-
associated disorders (Leverenz, Yu, and Schellenberg 1998).  Werner syndrome is also 
associated with loss of myelin fibers in both the central and peripheral nervous system 
(Umehara et al. 1993) although without the significant delays in neuronal development 
observed in CS. Werner syndrome is caused by a defect in Werner (WRN), a Rec-Q helicase 
which hydrolyzes ATP to separate double-stranded DNA for replication, recombination, 
transcription and repair (Monnat 2010).  The WRN protein is also essential for maintaining 
chromosomal integrity through intact recombination or DNA replication (Monnat 2010). 
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Many features of Werner syndrome are faithfully recapitulated in a mouse model in which 
the WRN gene is lacking the helicase domain (WRN∆hel/∆hel) (Huang et al. 2006; Lachapelle, 
Oesterreich, and Lebel 2011). WRN∆hel/∆hel mice have elevated levels of ROS and oxidative 
DNA damage in liver and heart, and elevated serum triglycerides, glucose and insulin; all of 
which return to wildtype level upon long-term vitamin C treatment (Lebel et al. 2010). WRN 
appears to play a role in protecting cells from oxidative damage, and the loss of WRN leads 
to changes resembling the metabolic syndrome.   
3.3 Ataxia Telangiectasia 
Deficiency in the DNA damage sensor ATM (Ataxia Telangiectasia Mutated) leads to ataxia 
telangiectasia (A-T). A-T is a rare autosomal disorder characterized by cerebellar ataxia, 
elevated cancer incidence, immune dysfunction and elevated sensitivity to ionizing 
radiation (Shackelford 2005). The life expectancy for patients with A-T is roughly 20 years 
(Chun and Gatti 2004).  A-T patients display signs of premature aging as well as insulin 
resistance and lowered insulin receptor affinity (Lavin 2000). Mouse models of ATM 
deficiency show an age-dependent increase in blood glucose and decrease in insulin 
sensitivity, consistent with a conserved role of this protein in metabolic function (Miles et al. 
2007). In an ApoE-/- mouse model, haploinsufficiency of ATM leads to accelerated 
atherosclerosis and multiple features of metabolic syndrome relative to the ApoE-/- mouse 
(Mercer et al. 2010). 
3.4 Seckel syndrome 
Stalled replication forks activate A-T and Rad-related protein (ATR), which leads to  
cell cycle checkpoint activation. Defective ATR signaling in humans causes Seckel 
syndrome, characterized by growth retardation and severe microcephaly (O'Driscoll and 
Jeggo 2008). While growth hormone secretion is normal, Seckel syndrome features high 
circulating IGF-1 levels and slightly decreased binding affinity for the IGF-1 receptor 
(Ducos et al. 2001; Schmidt et al. 2002). Whether this represents a constitutive defect  
in IGF-1 signalling or an adaptive response to a defective DNA damage response remains 
unknown.  
3.5 TP53 
Activation of the tumor suppressor p53 by genotoxic or other forms of stress can trigger 
various outcomes that reduce the chance of a damaged cell progressing into a tumor, 
ranging from cellular senescence to apoptosis. Besides its role in the response to genotoxic 
stress, p53 plays a central role in cellular energy metabolism through regulation of 
oxidative phosphorylation, glucose transporter expression and fatty acid synthase 
(Zhang, Qin, and Wang 2010). Mice engineered with defects in p53 are highly cancer 
prone, but also display a number of metabolic phenotypes. For example, phosphorylation 
of p53 at Ser18 by ATM is an important regulator of glucose homeostasis, as a S18A 
mutation renders mice insulin resistant (Armata et al. 2010). p53 is activated in adipose 
tissue upon high fat diet-induced obesity and insulin resistance in mice; inhibition of p53 
in adipose tissue rescues senescence and insulin resistance in diabetic mice (Minamino et 
al. 2009). Taken together, these data suggest that p53 activation, for example by oxidative 
stress derived from over-nutrition and potentially by isolated DNA damage, can promote 
the onset of metabolic syndrome. 
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3.6 DNA-PK, KU 
DNA-PK, Ku70 and Ku80 form a complex at double strand breaks to facilitate non-
homologous end joining (NHEJ). Mice deficient in the catalytic subunit of DNA-PK (DNA-
PKcs) exhibit accelerated aging, growth defects and decreased lifespan (Espejel et al. 2004). 
Mice deficient in Ku80 display premature aging symptoms including osteopenia, atrophic 
skin, hepatocellular degeneration and age-specific mortality; Ku70-/- mice display growth 
retardation (Gu et al. 1997; Vogel et al. 1999). Increased lymphoma and defects in B and T 
cells of DNA-PK, Ku70 and Ku80 mice are attributed to their lack of NHEJ resulting in 
deficient V(D)J recombination required for adaptive immunity; however, premature aging 
phenotypes are not seen in Rag-1 (V(D)J deficient) mice and thus not related to the lack of 
adaptive immunity and associated inflammation (Holcomb, Vogel, and Hasty 2007). 
Reduced size in Ku80 mice is not due to reduced IGF-1, but may instead be related to defects 
in cell-autonomous proliferation (van de Ven et al. 2006). 
3.7 NEIL1 DNA glycosylase deficiency 
NEIL1 glycoslyase is the homologue of the bacterial formamidopyrimidine DNA 
glycolyslase and initiates repair of oxidative lesions in BER, acting specifically on 2,6-
diamino-4-hydroxy-5-formamidopyrimidine and 4,6-diamino-5-formamidopyrimidine 
lesions (Jaruga, Birincioglu, et al. 2004). A mouse model deficient in NEIL-1 glycosylase 
develops severe obesity, dyslipidemia, fatty liver disease and hyperinsulinemia in the 
absence of exogenous oxidative stress (Vartanian et al. 2006).  The development of metabolic 
syndrome in NEIL1-/- mice is accelerated on a high-fat diet, indicating NEIL1 absence 
renders mice more susceptible to oxidative stress-induced metabolic syndrome (Sampath et 
al. 2011). Although no human diseases are associated with deficiency of NEIL1, several 
polymorphisms of NEIL1 with different activities on oxidized bases are found in humans 
(Roy et al. 2007). Whether or not these polymorphisms may lead to susceptibility to 
metabolic disease is not understood.   
3.8 SIRT6  
SIRT6 is the mammalian homologue of yeast Sir2 and is an NAD-dependent histone 
deacetylase. SIRT6 was originally described as a component of the BER system, as SIRT6 
deficient MEFs are hypersensitive to BER-lesion inducting agents such as methyl 
methanesulfonate and hydrogen peroxide; sensitivity was restored to that of wildtype by 
introducing the dRP lyase domain of Polβ (Mostoslavsky et al. 2006). Although no direct 
interaction between SIRT6 and BER factors has been reported to date, SIRT6 appears to 
impact DNA repair by stabilizing chromatin and facilitating DNA-PK dependent damage 
signaling (Lombard 2009; McCord et al. 2009). SIRT6 also influences metabolism both by 
deacetylating histone H3 lysine 9 and by repressing HIF1α to control the expression of 
glycolytic genes, which explains the glucose imbalance seen in SIRT6 knockout mice (Zhong 
et al. 2010). The SIRT6 phenotype is predominantly a metabolic one, with mice developing 
normally, although smaller than wildtypes, until 2 weeks of age, when they suffer from a 
degenerative wasting and severe hypoglycemia resulting in death (Mostoslavsky et al. 
2006). Like NER progeria, SIRT6 knockout mice also have reduced serum IGF-1, likely 
contributing to their small size. Neural-specific deletion of SIRT6 does not rescue the 
postnatal growth failure, but does rescue the severe hypoglycemia that leads to death in 
full-body knockouts of SIRT 6 (Schwer et al. 2010; Mostoslavsky et al. 2006). Neural-specific 
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SIRT6 mice survive much longer than the whole-body knockouts, and by one year of age 
become obese (Schwer et al. 2010). 
 
Syndrome Affected gene Metabolic feature 
Cockayne Syndrome CSA/CSB Loss of subcutaneous fat 
Trichothiodystrophy XPB/XPD/TTDA Loss of subcutaneous fat 
Hutchinson-Gilford 
Progeria Syndrome 
Lamin A Loss of subcutaneous fat, atheroslcerosis 
Werner Syndrome WRN 
Lipid accumulation in blood, insulin 
resistance 
Ataxia telangiectasia ATM Insulin resistance 
Seckel syndrome ATR Increased IGF-1 
Table 1. Human DNA repair diseases resulting in aberrant metabolism. 
4. Cell culture models 
In cultured cells, a number of recent studies on gene expression, signal transduction and 
protein interaction networks upon genotoxic stress point to both direct and indirect links 
between various forms of DNA damage and pathways regulating growth and energy 
metabolism.  
In mammals, organismal growth and metabolism are controlled by availability of nutrients 
and energy, which in turn influence secretion of circulating regulatory hormones including 
insulin from the pancreas, growth hormone from the pituitary, and growth-hormone 
dependent IGF-1 from the liver. Cellular responses to nutrients, energy and growth factor 
availability are controlled at the cell surface by receptor tyrosine kinases including the 
insulin receptor (IR) and IGF-1 receptor (IGF-1R). Binding of peptide hormones to their 
cognate receptors activates a signal transduction cascade resulting in the phosphorylation 
and activation of downstream kinases including AKT and mTOR. AKT exerts control over 
energy metabolism by phosphorylating and inactivating FOXO transcription factors as well 
as TSC1, a major negative regulator of mTOR. mTOR activation, which requires growth 
factors as well as nutrients (amino acids) and energy, results in phosphorylation and 
activation of ribosomal protein S6 kinase, promoting protein translation and increased cell 
size and growth. mTOR also phosphorylates and inactivates the translational repressor eIF-
4E-binding protein 1 (4EBP1), further promoting protein synthesis.  
The role of protein kinases in DNA repair and the DDR is firmly established. In response to 
ionizing radiation, DNA damage response proteins ATM and ATR phosphorylate 
checkpoint kinases Chk1 and Chk2, as well as p53 to block cell cycle progression (Stokes et 
al. 2007). The kinase DNA-PK, a PI3-type protein kinase in the same family as ATM and 
ATR, is directly involved in the repair of DNA double strand breaks through the process of 
NHEJ. However, each of these kinases can target additional substrates involved in growth 
and energy metabolism outside of canonical DNA repair and damage signaling pathways in 
response to growth factor stimulation. For example, DNA-PK is recruited by the upstream-
stimulatory factor to the promoter of fatty acid synthase (FAS), the master regulator of fatty 
acid synthesis, upon insulin stimulation (Wong et al. 2009).  DNA-PK is required for 
transient DNA breaks at the FAS promoter and transcription of FAS (Wong et al. 2009). 
ATM is required for phosphorylation of 4EBP1 on Ser 111 to promote protein anabolism 
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upon insulin stimulation (Yang and Kastan 2000). This may be due indirectly to 
phosphorylation and inactivation of the mTOR repressor TSC2 by ATM (Alexander et al. 
2010; Yang and Kastan 2000). ATM is also required for IGF-1 stimulated phosphorylation 
(activation) of AMPK, a cellular sensor of energy activated by low ATP/AMP ratios, to 
suppress energy-demanding processes such as cell growth in PANC and HeLa cells (Suzuki 
et al. 2004). ATM is also capable of inhibiting the stress signaling kinase JNK, whose activity 
is linked to several features of the metabolic syndrome (Schneider et al. 2006). Recently, 
ATM has been shown to be involved in the activation of autophagy through inhibition of 
mTOR (Alexander et al. 2010). DNA damage response proteins thus appear to be important 
regulators of cell growth and energy metabolism in response to environmental cues such as 
nutrient availability. 
Importantly, there is mounting evidence that DDR proteins can also control these same 
metabolic pathways in response to DNA damage. One of the first clues was that ATM 
regulates expression of the IGF-1R in response to ionizing radiation (Peretz et al. 2001). 
Subsequent analysis of the ATM and ATR substrate pathway following ionizing radiation 
revealed several connections to the insulin-IGF-1-AKT pathway, including previously 
unidentified substrates insulin receptor substrate 2 (IRS2), AKT3 and its regulators HSP90 
(heat shock protein 90) and PP2A (protein phosphatase 2A) (Matsuoka et al. 2007).  
Downstream targets of AKT including the transcription factor FOXO1, TSC1, S6K and 4E-
BP1 were also identified as ATM and/or ATR substrates (Matsuoka et al. 2007). Cells 
lacking ATM demonstrate elevated mTOR and glycerophospholipid pathways when 
exposed to ionizing radiation (Varghese et al. 2010). Upon UV irradiation, DNA-PK is also 
required for translational reprogramming by directly or indirectly targeting the amino acid 
deprivation sensor GCN2  (Powley et al. 2009). The net outcome of this signal transduction 
cascade is to reduce general translation while at the same time to increase translation of 
proteins involved in adaptation to DNA damage, including NER proteins.  
In addition to direct effects on cellular metabolism, activation of the DDR can trigger 
senescence-associated inflammatory cytokine secretion including IL-6 that can have an 
indirect effect on metabolism (Rodier et al. 2009).  In 3T3-L1 adipocytes, for example, IL-6 
inhibits phosphoenolpyruvate carboxykinase, which is required for triglyceride 
biosynthesis, thus increasing fatty acid mobilization (Feingold et al. 2011).   
Another target of DNA damage-induced signal transduction is the tumor suppressor p53. 
p53 is normally a short-lived protein, but stabilization by phosphorylation promotes its 
activity as a transcriptional activator of cell-cycle inhibitors such as p21. p53 is stabilized as a 
result of multiple forms of stress, including genotoxic stress from ionizing radiation, 
ultraviolet radiation and ROS. In addition to cell cycle targets, p53 targets include genes 
involved directly in glycolysis (repression of phosphoglycerate mutase, (Kondoh et al. 
2007)), and indirectly in respiration (activation of synthesis of cytochrome oxidase 2, a factor 
involved in COX assembly (Matoba et al. 2006)). In both cases, loss of p53 results in an 
increased glycolytic rate and decreased oxidative metabolism as is typically seen in cancer 
cells. TIGAR, another p53 target, is activated by low levels of stress and functions to repress 
glycolysis and to increase flux through the pentose phosphate pathway, resulting in 
increased generation of reduced glutathione, reduced ROS levels and protection from 
apoptosis (Bensaad et al. 2006). In some cells, glucose utilization by glycolysis competes 
with the pentose phosphate pathway responsible for generating NADPH reducing 
equivalents. Because NADPH is required for production of one of the major cellular 
antioxidants, reduced glutathione, increased glycolysis can come at the expense of 
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increased, rather than decreased, ROS. However, it is worth pointing out that this may be 
cell-type specific, as in other cells reduced glycolysis results in increased apoptosis. 
ATR may be the kinase responsible for phosphorylating and stabilizing p53 in response to 
genotoxic stress (Colman, Afshari, and Barrett 2000). ATR is recruited to stalled replication 
forks by the single strand DNA binding protein RPA and the ATR-interacting protein 
ATRIP. Single-stranded DNA regions serve as a platform for RPA-ATRIP-ATR recruitment 
in the context of stalled elongating replication machinery (Ljungman 2007). p53 can be also 
be stabilized even in the absence of DNA damage by inhibiting transcriptional elongation by 
RNA PolII (Bode and Dong 2004; Ljungman 2007). Thus, lesions that block an elongating 
RNA PolII and activate TC-NER can also signal through p53. Interestingly, the production 
of UV-induced DNA damage foci in quiescent fibroblasts requires ATR and is defective in 
primary cells from patients with Seckel syndrome (O'Driscoll et al. 2003).  
In cells deficient in TC-NER, unrepaired UV-induced lesions cause downregulation of both 
the GHR and IGF-1R (Garinis et al. 2009). This is consistent with the finding in NER 
progeroid mice of reduced insulin/IGF-1 signaling (Niedernhofer et al. 2006; van der Pluijm 
et al. 2007; van de Ven et al. 2006), and suggests that this effect can be cell autonomous in 
vivo rather than driven primarily by neuronal or neuroendocrine control. Interestingly, 
downregulation of growth receptors upon UV treatment was not inhibited in vitro by 
inhibitors of AKT, MAPK or JAK, but whether it requires DDR signaling through ATM, 
ATR or DNA-PK is not reported (Garinis et al. 2009). The identity of the signaling pathway 
from the lesion to receptor downregulation is currently not known.  
In addition to impacting cellular metabolism by activating signal transduction pathways, 
DNA damage repair pathways can also directly affect cellular energy status. PARP is 
activated upon oxidative base damage and consumes both ATP and NAD+ in the 
polyadenylation of various local substrates (Gagne et al. 2006), thus reducing available 
cellular energy currencies. Depending on the amount of damage and level of PARP 
activation, cellular energy stores can be depleted to pathological levels resulting in cell 
death. In the absence of exogenous DNA damage, PARP ablation results in increased 
NAD+ levels and increased activation of the NAD+-dependent deacetylase SIRT1, 
phenocopying aspects of SIRT1 deacetylase activation on mitochondrial metabolism (Bai 
et al. 2011). Thus, PARP provides a link between DNA damage and energy metabolism 
through direct effects on energy currencies as well as indirect effects of NAD+ and ATP 
dependent enzymes.  
5. Conclusions 
Cellular energy metabolism is a major source of ROS that can damage cellular components, 
including DNA. Oxidative DNA damage can in turn activate the DDR, a network of repair 
and signaling activities required for damage removal and stress adaptation. Inborn errors in 
DNA damage repair and signaling in human syndromes and mouse models typically 
display pathologies consistent with perturbation of growth and energy metabolism, 
including dwarfism and changes in insulin signaling and lipid accumulation. Interestingly, 
some disorders present with phenotypes reminiscent of the maladaptive response to 
nutrient/energy excess seen in metabolic syndrome. For example, in in A-T and Werner 
syndrome, these symptoms include dyslipidemia and insulin resistance. In other disorders, 
including mouse models of CS and TTD, symptoms appear on the opposite end of the 
nutrient/energy spectrum, with hypoglycemia, increased insulin sensitivity and reduced 
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adiposity reminiscent of the beneficial adaptations to DR. Over time, however, chronic 
activation of adaptations such as reduced IGF-1 that may be beneficial in the context of a 
wildtype mammal on a restricted diet may in fact become maladaptive in the context of 
genome instability. For example, mouse models of severe NER progeria have reduced IGF-1, 
but nonetheless have shortened lifespans, while restoration of IGF-1 levels in a mouse 
model of HGPS ameliorates disease symptoms. On the cellular level, recent data suggest 
that proteins involved in the DNA damage response can exert both direct and indirect 
control over pathways involved in energy metabolism and substrate utilization, including 
insulin and IGF-1 signaling. Which of these genetic defects leads to constitutive alterations 
in metabolic processes and which to adaptive responses to genotoxic stress remains to be 
fully elucidated. Furthermore, to what degree unrepaired DNA damage itself serves as the 
trigger for metabolic changes, and the identity of the causative lesion, is in most cases 
unknown. In conclusion, despite recent emerging data on a connection between the DNA 
damage response and energy metabolism, there is a relative dearth of studies on cellular or 
organismal energy metabolism in the context of genome instability disorders, with much 
remaining to be done in this burgeoning field. 
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